Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are now in widespread use for a plethora of retinal diseases. It is recognised that there is a transient intraocular pressure (IOP) rise after intravitreal anti-VEGF therapy although the exact mechanism of this is unclear.
In most patients the IOP normalises but in approximately 10% patients there is a sustained pressure elevation (2,4). Patients with ocular hypertension or glaucoma and patients having repeated intravitreal anti-VEGF injections appear to be more susceptible to the IOP rise and delayed recovery (1-4). Repeated anti-VEGF injections may also increase the future risk of developing glaucoma or ocular hypertension (3).
IOP monitoring, prophylactic measures or an adjustment in injection interval should be considered when administering repeated intravitreal anti-VEGF injections, particularly in glaucoma patients.
Contributor: Humma Shahid, Cambridge, UK
References
Tip Reviewer: Roger Hitchings
Tip Editors: Frances Meier-Gibbons, Humma Shahid, Karl Mercieca, Francisco Goni